PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M

Gross Profit

$11M100.0% margin

Operating Income

-$8M-76.3% margin

Net Income

-$8M-71.1% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-4.4%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$149M

Total Liabilities

$35M

Stockholders' Equity

$115M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$0	—
Gross Profit	$11M	$0	—
Operating Income	-$8M	-$14M	+42.3%
Net Income	-$8M	-$14M	+45.7%

Revenue Segments

License And Collaborative Revenue

$11M100%

PTGX Q1 2018 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena